Therapeutically Applicable Research to Generate Effective Treatments (TARGET) for Osteosarcoma
- To comprehensively detect genomic, epigenomic, and transcriptomic aberrations in tissue
samples from patients with osteosarcoma that may play a role in chemoresistance and
metastasis using high-resolution genome-wide technologies.
- To identify recurrent genetic mutations involved in the pathogenesis of osteosarcoma,
especially for the development of chemoresistance and metastatic tumors.
- To identify and validate these biomarkers for new therapeutic targets for patients with
osteosarcoma, especially those with metastatic disease and whose tumors are resistant
to standard chemotherapy.
OUTLINE: This is a multicenter study.
Archived tumor tissue and peripheral blood DNA specimens are analyzed for DNA copy number
profiling, gene expression profiling, DNA methylation profiling, microRNA profiling, and
genomic resequencing. Clinical data including demographics; date of diagnosis, surgery,
chemotherapy, recurrence, progression, and death; imaging; toxicity; and pathologic data
elements associated with the specimens are also collected and analyzed.
Identification and validation of biomarkers with potential clinical utility
Ching C. Lau, MD, PhD
Texas Children's Cancer Center
United States: Federal Government